Keywords: genzyme, delivers, 4th-qtr, revenue, growth, under, expectations
Genzyme delivers 22% 4th-qtr 2005 revenue growth, just under expectations
Article | 16 January 2006
US biotechnology major Genzyme presented a solid set of preliminary results for fourth-quarter 2005, with 22% revenue growth on the like, year-ago ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
